Institutional & Family Asset Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 4.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,411 shares of the company’s stock after acquiring an additional 1,502 shares during the quarter. Institutional & Family Asset Management LLC’s holdings in Johnson & Johnson were worth $4,214,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. IHT Wealth Management LLC grew its position in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $177,000. 67.35% of the stock is owned by institutional investors.
A number of equities research analysts have recently commented on JNJ shares. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets boosted their price target on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price target for the company in a research report on Wednesday, December 20th. JPMorgan Chase & Co. downgraded Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $146.26.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE JNJ) opened at $133.68 on Friday. The company has a market capitalization of $356,986.94, a PE ratio of 342.77, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. sell-side analysts expect that Johnson & Johnson will post 8.11 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 861.54%.
ILLEGAL ACTIVITY WARNING: This news story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/17/institutional-family-asset-management-llc-has-4-21-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.